Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 116INDUSTRY 23NIH 18NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 20Lymphoid 5Other hematologic neoplasm 3Myeloid 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Cytarabine 83Methotrexate 59Cyclophosphamide 58Vincristine 47Daunorubicin 46Prednisone 33Mercaptopurine 33Asparaginase 33Dexamethasone 31Doxorubicin 29Gene Expression Profiling 27Etoposide 27pegaspargase 25Radiotherapy 25Filgrastim 25Thioguanine 24Leucovorin 24Flow Cytometry 23merphos 22Hydrocortisone 20Calcium Dobesilate 20Specimen Handling 18Microarray Analysis 16Idarubicin 16Granulocyte Colony-Stimulating Factor 15Peripheral Blood Stem Cell Transplantation 14Busulfan 14Polymerase Chain Reaction 13Mitoxantrone 13Gemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Lenalidomide × Other hematologic neoplasm × Clear all
NCT01460420 2017-07-06

EMN-alloRIC

European Myeloma Network B.V.

Phase 1/2 Completed
49 enrolled
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT01556477 2012-03-16

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Nordic MDS Group

Phase 2 Unknown
72 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00628238 2010-09-10

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia Research Consortium

Phase 2 Unknown
80 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡